---
title: "Bone-Conducted Ultrasonic Auditory Brainstem Response and Cisplatin-Induced Hearing Loss in Mice"
id: "plos-one-8-bone-conducted-ultrasonic-auditory-brainstem-response-thresholds-in-a-mouse"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-8-bone-conducted-ultrasonic-auditory-brainstem-response-thresholds-in-a-mouse"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0353954"
published_at: "2026-07-16T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Bone-Conducted Ultrasonic Auditory Brainstem Response and Cisplatin-Induced Hearing Loss in Mice
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-8-bone-conducted-ultrasonic-auditory-brainstem-response-thresholds-in-a-mouse
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0353954)
- **Published At:** 2026-07-16T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Cisplatin is effective against various cancers but causes irreversible hearing loss, typically affecting high frequencies. - This study aimed to investigate auditory brainstem response (ABR) thresholds using bone-conducted ultrasonic stimulation in a mouse model. - Out of 32 examined mice, 9 were excluded due to pre-existing hearing impairment, resulting in 16 for analysis post-cisplatin treatment. - After cisplatin treatment, ABR thresholds in conventional hearing ranges significantly increased, while shifts from ultrasonic stimulation remained relatively smaller. - Results indicate that responses to bone-conducted ultrasonic stimulation do not parallel the changes seen in conventional ABR testing, suggesting different cochlear response mechanisms could be at play.
## Clinical Analysis & Structured Key Points
1. Abstract 2. Introduction 3. Materials and Methods 1. Ethical Approval 2. Animals and Experimental Procedures 3. Calibration of Bone-Conducted Sound and Ultrasound Stimulation 4. Electrophysiological Measurements 5. Statistical Analysis 4. Results 1. Cisplatin Administration and ABR Measurements 2. Relationship Between Threshold Shifts 5. Discussion
## Related Clinical Research

- [Pollen size shifts after whole genome duplication in autotetraploids](https://medichelpline.com/clinical-feed/biorxiv-17-biased-evolution-of-pollen-size-after-whole-genome-duplication.md)
- [Chemosensory System Evolution in Actinomycetota: Polyphyly and Lineage-Specific Expansion](https://medichelpline.com/clinical-feed/biorxiv-5-polyphyletic-origins-and-lineage-specific-expansion-of-chemosensory-systems-in.md)
- [Correction: Updated Data Availability DOI for Bone-Conducted Ultrasonic ABR Study in Cisplatin Hea](https://medichelpline.com/clinical-feed/plos-one-2-correction-bone-conducted-ultrasonic-auditory-brainstem-response-thresholds-in.md)
- [Urgent BEP chemotherapy in advanced primary mediastinal malignant germ cell tumor: Case and review](https://medichelpline.com/clinical-feed/pubmed-43063085.md) (DOI: 10.1097/MD.0000000000051609)
- [Correction: Image replacement and data notes for niosomal cisplatin–vorinostat formulation](https://medichelpline.com/clinical-feed/plos-one-19-correction-development-of-niosomal-nanoparticles-loaded-with-cisplatin-and.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.